Hidehito Horinouchi (堀之内 秀仁) , M.D., Ph.D.

Hidehito Horinouchi’s story

Dr. Horinouchi is an expert in thoracic medical oncology, focusing on the development of new drug therapies and multimodal treatments for thoracic malignancies. He is deeply involved in clinical trials as the general secretary of JCOG (Japan Clinical Oncology Group). Additionally, Dr. Horinouchi contributes to the education and professional development of young oncologists, having played a pivotal role in the creation of educational programs at the National Cancer Center Hospital and across academic societies like JSMO and JLCS.

Research Interest

• New drug development and multimodality treatment for thoracic malignancies, including chemotherapy, radiotherapy, surgery, and immunotherapy. Focused on clinical trials and advancing thoracic cancer care.

Qualifications, certified physicians, medical specialists

• Member, Japan Lung Cancer Society (JLCS)
• Member, Japanese Society of Medical Oncology (JSMO)
• Member, Japan Respiratory Society
• Member, International Association for the Study of Lung Cancer (IASLC)
• Member, American Society of Clinical Oncology (ASCO)
• Member, European Society of Medical Oncology (ESMO)
• Member, American Association for Cancer Research (AACR)
• Member, Multinational Association of Supportive Care in Cancer (MASCC)

Specialized field

• Thoracic oncology, including lung cancer, esophageal cancer, and other thoracic malignancies.

Professional Experience

• Chief, Office for Patient Flow Management, National Cancer Center Hospital (2021–Present)
• Deputy Chief, Center for Education and Professional Career Development, National Cancer Center Hospital (2018–Present)
• Chief, Office for Professional Education Management, National Cancer Center Hospital (2014–Present)
• Chief, Physician Referral Service Office, National Cancer Center Hospital (2013–2018)
• Assistant Chief, Department of Thoracic Oncology, National Cancer Center Hospital (2013–Present)